Cingulate Inc. CING
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Cingulate Inc. (CING) is a healthcare company listed in the US with a market value of about $63M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -114%.
About Cingulate
Cingulate is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 9971% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$22M | -$17M | -$24M | -$18M | -$21M | -$7M |
| Free cash flow | -$17M | -$19M | -$15M | -$16M | -$11M | -$7M |
| EPS (diluted) | $-1.48 | $-3.62 | $-104.00 | $-117.40 | $-11.16 | — |
| Net margin | — | — | — | — | — | — |
| ROIC | -139.5% | -98.5% | — | -142.4% | -74.4% | -181.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $21.20, 393% above the current price; targets range from $8.00 to $44.00; the consensus rating is “none”; expected EPS is $-2.19 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Cingulate pay a dividend?
Not currently.
Is Cingulate a good stock to buy?
We do not give buy or sell advice. Cingulate scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.